CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 215 enrolled
Drug / intervention
SYM-1219 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02147899
NCT02147899Phase 2Completed
CompareCT.gov

A Phase 2, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 for the Treatment of Women With Bacterial Vaginosis

Symbiomix Therapeutics·interventional·Posted May 28, 2014·Updated Nov 13, 2020

In Brief

A Phase 2 clinical trial evaluating SYM-1219 and Placebo for Bacterial Vaginosis. Completed, enrolled 215 participants across 16 sites.

Detailed Summary

The purpose of this research study is to test the safety and effectiveness of the oral investigational new drug, SYM-1219, for the treatment of bacterial vaginosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Vaginosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 28, 2014
Enrollment StartMay 1, 2014
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.1 years ago

Interventions

SYM-1219drug

Oral

Placebodrug

Oral